{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:13:57Z","timestamp":1791530037988,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"7968","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2023,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Vaccination with Sabin, a live attenuated oral polio vaccine (OPV), results in robust intestinal and humoral immunity and has been key to controlling poliomyelitis. As with any RNA virus, OPV evolves rapidly to lose attenuating determinants critical to the reacquisition of virulence\n                    <jats:sup>1\u20133<\/jats:sup>\n                    resulting in vaccine-derived, virulent poliovirus variants. Circulation of these variants within underimmunized populations leads to further evolution of circulating, vaccine-derived poliovirus with higher transmission capacity, representing a significant risk of polio re-emergence. A new type\u20092 OPV (nOPV2), with promising clinical data on genetic stability and immunogenicity, recently received authorization from the World Health Organization for use in response to circulating, vaccine-derived poliovirus outbreaks. Here we report the development of two additional live attenuated vaccine candidates against type\u20091 and 3 polioviruses. The candidates were generated by replacing the capsid coding region of nOPV2 with that from Sabin\u20091 or 3. These chimeric viruses show growth phenotypes similar to nOPV2 and immunogenicity comparable to their parental Sabin strains, but are more attenuated. Our experiments in mice\u00a0and deep sequencing\u00a0analysis confirmed that the candidates remain attenuated and preserve all the documented nOPV2 characteristics concerning genetic stability following accelerated virus evolution. Importantly, these vaccine candidates are highly immunogenic in mice as monovalent and multivalent formulations and may contribute to poliovirus eradication.\n                  <\/jats:p>","DOI":"10.1038\/s41586-023-06212-3","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T12:02:03Z","timestamp":1686744123000},"page":"135-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3"],"prefix":"10.1038","volume":"619","author":[{"given":"Ming Te","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7158-8134","authenticated-orcid":false,"given":"Sarah","family":"Carlyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Konopka-Anstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara C.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-5540","authenticated-orcid":false,"given":"John","family":"Konz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-9349","authenticated-orcid":false,"given":"Raul","family":"Andino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8687-1573","authenticated-orcid":false,"given":"Andrew","family":"Macadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"6212_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2017.03.013","volume":"169","author":"A Stern","year":"2017","unstructured":"Stern, A. et al. The evolutionary pathway to virulence of an RNA virus. Cell 169, 35\u201346 (2017).","journal-title":"Cell"},{"key":"6212_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/0966-842X(94)90803-6","volume":"2","author":"AJ Macadam","year":"1994","unstructured":"Macadam, A. J., Stone, D. M., Almond, J. W. & Minor, P. D. The 5\u2019 noncoding region and virulence of poliovirus vaccine strains. Trends Microbiol. 2, 449\u2013454 (1994).","journal-title":"Trends Microbiol."},{"key":"6212_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1006\/viro.1993.1003","volume":"192","author":"AJ Macadam","year":"1993","unstructured":"Macadam, A. J. et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192, 18\u201326 (1993).","journal-title":"Virology"},{"key":"6212_CR4","unstructured":"WHO. Two out of Three Wild Poliovirus Strains Eradicated; https:\/\/www.who.int\/news-room\/feature-stories\/detail\/two-out-of-three-wild-poliovirus-strains-eradicated (2019)."},{"key":"6212_CR5","unstructured":"WHO. Poliomyelitis https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/poliomyelitis (2022)."},{"key":"6212_CR6","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","volume":"210","author":"CC Burns","year":"2014","unstructured":"Burns, C. C., Diop, O. M., Sutter, R. W. & Kew, O. M. Vaccine-derived polioviruses. J. Infect. Dis. 210, S283\u2013293 (2014).","journal-title":"J. Infect. Dis."},{"key":"6212_CR7","doi-asserted-by":"publisher","first-page":"11097","DOI":"10.1128\/JVI.78.20.11097-11107.2004","volume":"78","author":"S Guest","year":"2004","unstructured":"Guest, S., Pilipenko, E., Sharma, K., Chumakov, K. & Roos, R. P. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J. Virol. 78, 11097\u201311107 (2004).","journal-title":"J. Virol."},{"key":"6212_CR8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nbt.1635","volume":"28","author":"AS Lauring","year":"2010","unstructured":"Lauring, A. S., Jones, J. O. & Andino, R. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28, 573\u2013579 (2010).","journal-title":"Nat. Biotechnol."},{"key":"6212_CR9","unstructured":"GPEI. Polio Eradication Strategy 2022\u20132026: Delivering on a Promise https:\/\/polioeradication.org\/gpei-strategy-2022-2026\/ (2021)."},{"key":"6212_CR10","doi-asserted-by":"publisher","first-page":"101508","DOI":"10.1016\/j.eclinm.2022.101508","volume":"50","author":"YA Lai","year":"2022","unstructured":"Lai, Y. A., Chen, X., Kunasekaran, M., Rahman, B. & MacIntyre, C. R. Global epidemiology of vaccine-derived poliovirus 2016\u20132021: a descriptive analysis and retrospective case-control study. EClinicalMedicine 50, 101508 (2022).","journal-title":"EClinicalMedicine"},{"key":"6212_CR11","unstructured":"WHO. Global Circulating Vaccine-Derived Poliovirus (cVDPV) as of 31 January 2023; https:\/\/polioeradication.org\/wp-content\/uploads\/2023\/02\/weekly-polio-analyses-cVDPV-20230131.pdf (2023)."},{"key":"6212_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1126\/science.aba1238","volume":"368","author":"GR Macklin","year":"2020","unstructured":"Macklin, G. R. et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science 368, 401\u2013405 (2020).","journal-title":"Science"},{"key":"6212_CR13","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1128\/JCM.37.6.1670-1675.1999","volume":"37","author":"Y Manor","year":"1999","unstructured":"Manor, Y. et al. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. J. Clin. Microbiol. 37, 1670\u20131675 (1999).","journal-title":"J. Clin. Microbiol."},{"key":"6212_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.15585\/mmwr.mm7133e2","volume":"71","author":"R Link-Gelles","year":"2022","unstructured":"Link-Gelles, R. et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater \u2014 New York, June\u2013August 2022. MMWR Morb. Mort. Wkly Rep. 71, 1065\u20131068 (2022).","journal-title":"MMWR Morb. Mort. Wkly Rep."},{"key":"6212_CR15","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.15585\/mmwr.mm7144e2","volume":"71","author":"AB Ryerson","year":"2022","unstructured":"Ryerson, A. B. et al. Wastewater testing and detection of poliovirus type 2 genetically linked to virus isolated from a paralytic polio case \u2014 New York, March 9\u2013October 11, 2022. MMWR Morb. Mort. Wkly Rep. 71, 1418\u20131424 (2022).","journal-title":"MMWR Morb. Mort. Wkly Rep."},{"key":"6212_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0042-6822(92)90565-7","volume":"189","author":"AJ Macadam","year":"1992","unstructured":"Macadam, A. J. et al. Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology 189, 415\u2013422 (1992).","journal-title":"Virology"},{"key":"6212_CR17","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1128\/JVI.00370-06","volume":"80","author":"AJ Macadam","year":"2006","unstructured":"Macadam, A. J. et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol. 80, 8653\u20138663 (2006).","journal-title":"J. Virol."},{"key":"6212_CR18","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","volume":"27","author":"MT Yeh","year":"2020","unstructured":"Yeh, M. T. et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe 27, 736\u2013751 (2020).","journal-title":"Cell Host Microbe"},{"key":"6212_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00437-5","volume":"7","author":"R Wahid","year":"2022","unstructured":"Wahid, R. et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines 7, 19 (2022).","journal-title":"NPJ Vaccines"},{"key":"6212_CR20","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1016\/S2666-5247(22)00254-3","volume":"3","author":"R Wahid","year":"2022","unstructured":"Wahid, R. et al. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials. Lancet Microbe 3, e912\u2013e921 (2022).","journal-title":"Lancet Microbe"},{"key":"6212_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00355-y","volume":"6","author":"R Wahid","year":"2021","unstructured":"Wahid, R. et al. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. NPJ Vaccines 6, 94 (2021).","journal-title":"NPJ Vaccines"},{"key":"6212_CR22","doi-asserted-by":"publisher","first-page":"100102","DOI":"10.1016\/j.jvacx.2021.100102","volume":"8","author":"JO Konz","year":"2021","unstructured":"Konz, J. O. et al. Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine. Vaccine X 8, 100102 (2021).","journal-title":"Vaccine X"},{"key":"6212_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(20)32541-1","volume":"397","author":"ID Coster","year":"2021","unstructured":"Coster, I. D. et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet 397, 39\u201350 (2021).","journal-title":"Lancet"},{"key":"6212_CR24","unstructured":"WHO. First Ever Vaccine Listed Under WHO Emergency Use; https:\/\/www.who.int\/news\/item\/13-11-2020-first-ever-vaccine-listed-under-who-emergency-use (2020)."},{"key":"6212_CR25","doi-asserted-by":"publisher","first-page":"e1807","DOI":"10.1016\/S2214-109X(22)00412-0","volume":"10","author":"A Mirzoev","year":"2022","unstructured":"Mirzoev, A. et al. Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. Lancet Glob. Health 10, e1807\u2013e1814 (2022).","journal-title":"Lancet Glob. Health"},{"key":"6212_CR26","unstructured":"WHO. Statement of the Thirtieth Polio IHR Emergency Committee; https:\/\/www.who.int\/news\/item\/23-11-2021-statement-of-the-thirtieth-polio-ihr-emergency-committee (2021)."},{"key":"6212_CR27","doi-asserted-by":"publisher","unstructured":"Bandyopadhyay, A. S. & Zipursky, S. A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/s1473-3099(22)00582-5 (2022).","DOI":"10.1016\/s1473-3099(22)00582-5"},{"key":"6212_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1473-3099(20)30555-7","volume":"21","author":"AS Bandyopadhyay","year":"2021","unstructured":"Bandyopadhyay, A. S. et al. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect. Dis. 21, 559\u2013568 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"6212_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","volume":"397","author":"X S\u00e1ez-Llorens","year":"2021","unstructured":"S\u00e1ez-Llorens, X. et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet 397, 27\u201338 (2021).","journal-title":"Lancet"},{"key":"6212_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","volume":"394","author":"PV Damme","year":"2019","unstructured":"Damme, P. V. et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet 394, 148\u2013158 (2019).","journal-title":"Lancet"},{"key":"6212_CR31","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1128\/JVI.74.10.4590-4600.2000","volume":"74","author":"I Goodfellow","year":"2000","unstructured":"Goodfellow, I. et al. Identification of a cis-acting replication element within the poliovirus coding region. J. Virol. 74, 4590\u20134600 (2000).","journal-title":"J. Virol."},{"key":"6212_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/risa.13622","volume":"41","author":"DA Kalkowska","year":"2021","unstructured":"Kalkowska, D. A. et al. Updated characterization of outbreak response strategies for 2019\u20132029: impacts of using a novel type 2 oral poliovirus vaccine strain. Risk Anal. 41, 329\u2013348 (2021).","journal-title":"Risk Anal."},{"key":"6212_CR33","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1128\/jvi.63.3.1338-1344.1989","volume":"63","author":"GD Westrop","year":"1989","unstructured":"Westrop, G. D. et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 63, 1338\u20131344 (1989).","journal-title":"J. Virol."},{"key":"6212_CR34","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1128\/jvi.65.3.1377-1382.1991","volume":"65","author":"RB Ren","year":"1991","unstructured":"Ren, R. B., Moss, E. G. & Racaniello, V. R. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J. Virol. 65, 1377\u20131382 (1991).","journal-title":"J. Virol."},{"key":"6212_CR35","doi-asserted-by":"publisher","first-page":"20063","DOI":"10.1073\/pnas.1012537107","volume":"107","author":"A Neverov","year":"2010","unstructured":"Neverov, A. & Chumakov, K. Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. Proc. Natl Acad. Sci. USA 107, 20063\u201320068 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"6212_CR36","unstructured":"WHO. Neurovirulence Test of Types 1, 2 or 3 Live Attenuated Poliomyelitis Vaccines (Oral) in Transgenic Mice Susceptible to Poliovirus; https:\/\/www.who.int\/publications\/m\/item\/neurovirulence-test-sop-of-types-1-2-or-3-opv-in-transgenic-mice-susceptible-to-poliovirus (2015)."},{"key":"6212_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1128\/MMBR.65.1.151-185.2001","volume":"65","author":"IM Rouzine","year":"2001","unstructured":"Rouzine, I. M., Rodrigo, A. & Coffin, J. M. Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol. Mol. Biol. Rev. 65, 151\u2013155 (2001).","journal-title":"Microbiol. Mol. Biol. Rev"},{"key":"6212_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1006\/viro.2000.0244","volume":"269","author":"A Rowe","year":"2000","unstructured":"Rowe, A., Ferguson, G. L., Minor, P. D. & Macadam, A. J. Coding changes in the poliovirus protease 2A compensate for 5\u2019NCR domain V disruptions in a cell-specific manner. Virology 269, 284\u2013293 (2000).","journal-title":"Virology"},{"key":"6212_CR39","doi-asserted-by":"publisher","first-page":"786","DOI":"10.15585\/mmwr.mm7124a2","volume":"71","author":"J Martin","year":"2022","unstructured":"Martin, J. et al. Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing \u2014 worldwide, March\u2013October 2021. MMWR Morbid. Mort. Wkly Rep. 71, 786\u2013790 (2022).","journal-title":"MMWR Morbid. Mort. Wkly Rep."},{"key":"6212_CR40","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1099\/0022-1317-67-7-1283","volume":"67","author":"PD Minor","year":"1986","unstructured":"Minor, P. D., Ferguson, M., Evans, D. M. A., Almond, J. W. & Icenogle, J. P. Antigenic structure of polioviruses of serotypes 1, 2 and 3. J. Gen. Virol. 67, 1283\u20131291 (1986).","journal-title":"J. Gen. Virol."},{"key":"6212_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.molimm.2014.07.014","volume":"63","author":"L Bannwarth","year":"2015","unstructured":"Bannwarth, L. et al. Structural studies of virus\u2013antibody immune complexes (poliovirus type I): characterization of the epitopes in 3D. Mol. Immunol. 63, 279\u2013286 (2015).","journal-title":"Mol. Immunol."},{"key":"6212_CR42","doi-asserted-by":"crossref","unstructured":"Gast, C. et al. Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV\/IPV-vaccinated infants: two randomized clinical trials. J. Infect. Dis. 226, jiab507 (2021).","DOI":"10.1093\/infdis\/jiab507"},{"key":"6212_CR43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1006\/viro.1995.1268","volume":"209","author":"RE Taffs","year":"1995","unstructured":"Taffs, R. E. et al. Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions. Virology 209, 366\u2013373 (1995).","journal-title":"Virology"},{"key":"6212_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/infdis\/jiaa783","volume":"226","author":"EB Brickley","year":"2020","unstructured":"Brickley, E. B. et al. Intestinal antibody responses to 2 novel live attenuated type 2 oral poliovirus vaccines in healthy adults in Belgium. J. Infect. Dis. 226, 287\u2013291 (2020).","journal-title":"J. Infect. Dis."},{"key":"6212_CR45","unstructured":"PATH. Study of novel types 1 and 3 oral poliomyelitis vaccines. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04529538 (2023)."},{"key":"6212_CR46","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2217\/fmb.15.19","volume":"10","author":"AS Bandyopadhyay","year":"2015","unstructured":"Bandyopadhyay, A. S., Garon, J., Seib, K. & Orenstein, W. A. Polio vaccination: past, present and future. Future Microbiol. 10, 791\u2013808 (2015).","journal-title":"Future Microbiol."},{"key":"6212_CR47","unstructured":"GPEI. GPEI Statement on cVDPV2 Detections in Burundi and Democratic Republic of the Congo; https:\/\/polioeradication.org\/news-post\/gpei-statement-on-cvdpv2-detections-in-burundi-and-democratic-republic-of-the-congo\/ (2023)."},{"key":"6212_CR48","unstructured":"Roberts, L. Polio cases in Africa linked to new oral vaccine. Science https:\/\/www.science.org\/content\/article\/first-polio-cases-linked-new-oral-vaccine-detected-africa (2023)."},{"key":"6212_CR49","doi-asserted-by":"crossref","unstructured":"Burrill, C. P., Strings, V. R. & Andino, R. Poliovirus: generation, quantification, propagation, purification, and storage. Curr. Protoc. Microbiol. Ch. 15, 15H.1.1\u201315H.1.27 (2013).","DOI":"10.1002\/9780471729259.mc15h01s29"},{"key":"6212_CR50","doi-asserted-by":"crossref","unstructured":"Hierholzer, J. C. & Killington, R. A. Virus isolation and quantitation. Virology Methods Manual 1996, 25\u201346 (2007).","DOI":"10.1016\/B978-012465330-6\/50003-8"},{"key":"6212_CR51","doi-asserted-by":"publisher","first-page":"11189","DOI":"10.1093\/nar\/gks918","volume":"40","author":"A Wilm","year":"2012","unstructured":"Wilm, A. et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 40, 11189\u201311201 (2012).","journal-title":"Nucleic Acids Res."},{"key":"6212_CR52","doi-asserted-by":"publisher","first-page":"e1005316","DOI":"10.1371\/journal.ppat.1005316","volume":"11","author":"S Knowlson","year":"2015","unstructured":"Knowlson, S. et al. New strains intended for the production of inactivated polio vaccine at low-containment after eradication. PLoS Pathog. 11, e1005316 (2015).","journal-title":"PLoS Pathog."},{"key":"6212_CR53","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/0076-6879(86)18114-6","volume":"118","author":"MF Clark","year":"1986","unstructured":"Clark, M. F., Lister, R. M. & Bar-Joseph, M. ELISA techniques. Methods Enzymol. 118, 742\u2013766 (1986).","journal-title":"Methods Enzymol."},{"key":"6212_CR54","unstructured":"Holm, S. A simple sequentially rejective multiple test procedure. Scand. Stat. Theory Appl. 6, 65\u201370 (2019)."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06212-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06212-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06212-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T02:09:17Z","timestamp":1688609357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-06212-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":54,"journal-issue":{"issue":"7968","published-print":{"date-parts":[[2023,7,6]]}},"alternative-id":["6212"],"URL":"https:\/\/doi.org\/10.1038\/s41586-023-06212-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2306887\/v1","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"assertion":[{"value":"23 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}